Healthcare Web Wire

Author: Elena Morales

Biomarkers Market Key Trends, Companies and Future Outlook
Biomarkers Market Size, Grow and Trends

The biomarkers market was valued at approximately $82.35 billion in 2023 and is expected to grow significantly, reaching around $366.6 billion by 2034. This represents a strong annual growth rate of 14.54% over the forecast period from 2024 to 2034.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5322

Biomarkers Market Trends
- Rising Demand for Personalized Medicine: As healthcare becomes more personalized, biomarkers play a crucial role in identifying patients who are most likely to respond to specific treatments, leading to better outcomes.
- Advancements in Technology: Cutting-edge technologies such as next-generation sequencing (NGS) and liquid biopsy are improving the accuracy of biomarker identification, paving the way for more precise diagnostics and treatment monitoring.
- Increased Focus on Early Disease Detection: Biomarkers are increasingly being used for early detection of diseases like cancer, cardiovascular conditions, and neurological disorders, which is helping to improve prognosis and reduce treatment costs.
- Growing Investments in R&D: Significant investments in research and development are accelerating the discovery of new biomarkers for various diseases, enhancing the market’s growth potential.
- Regulatory Approvals and Collaborations: More biomarkers are receiving regulatory approvals for clinical use, and partnerships between pharmaceutical companies and research institutions are expanding, helping to bring new biomarker-based diagnostics to the market.
Leading Companies in the Biomarkers Market
- Abbott: A global healthcare leader, Abbott is actively involved in the development and application of biomarkers, particularly in diagnostics and personalized medicine. Their focus on innovative testing solutions aims to improve disease detection and patient care.
- Alto Neuroscience, Inc.: Specializing in neuroscience, Alto Neuroscience is pioneering the use of biomarkers for mental health. The company is focused on developing precision treatments for psychiatric disorders based on biological insights.
- Hanmi Pharmaceutical: Based in South Korea, Hanmi Pharmaceutical is investing in the development of biomarker-driven treatments, particularly in oncology and autoimmune diseases. The company is committed to advancing personalized healthcare solutions.
- Hoffmann-La Roche Ltd.: Roche is a major player in the biomarkers space, with a strong portfolio in diagnostics and pharmaceuticals. The company is at the forefront of using biomarkers for early disease detection and personalized treatment plans, particularly in cancer and genetic disorders.
- Johnson & Johnson: With its broad healthcare portfolio, Johnson & Johnson is making strides in the use of biomarkers for drug discovery, diagnostics, and precision medicine. The company is focused on improving patient outcomes by integrating biomarker research into its therapeutic areas.
- Labcorp Biopharma: A leading provider of clinical laboratory services, Labcorp Biopharma offers extensive biomarker testing services to support drug development and personalized treatment strategies. The company is focused on advancing precision medicine through its innovative diagnostic tools.
- MEDiC Life Sciences: MEDiC Life Sciences is focused on utilizing biomarkers for the early detection of diseases, particularly in cancer. Their research and development efforts aim to advance non-invasive diagnostic tools for better clinical outcomes.
- Qiagen: A global leader in molecular diagnostics, Qiagen provides a wide range of biomarker-based solutions for disease detection and drug development. The company is known for its expertise in genetic testing and biomarker analysis, which plays a key role in personalized healthcare.
- Regeneron: Known for its innovative approach to biotechnology, Regeneron is leveraging biomarkers to develop targeted therapies, particularly in the areas of oncology and immunology. The company uses biomarker data to enhance the efficacy of its treatments.
- Sanofi: A global healthcare giant, Sanofi is focusing on integrating biomarkers into drug development processes, especially in immunology, oncology, and rare diseases. The company is advancing precision medicine by utilizing biomarkers for better-targeted treatments.
- Siemens Healthineers: Siemens Healthineers is a leader in diagnostic imaging and laboratory diagnostics, and they are incorporating biomarkers into their solutions to improve disease detection and monitoring. The company is committed to advancing healthcare through innovative biomarker technologies.
- Thermo Fisher Scientific: A key player in the life sciences sector, Thermo Fisher Scientific provides a wide array of biomarker discovery and testing tools. The company’s technologies are used across pharmaceutical, clinical, and research settings to enable the development of precision medicine solutions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/biomarkers-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5322

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 18, 2024
Sterile Disposable Vacuum Blood Collection Tube Market Innovations and Growth Analysis
Growth Trends in the Sterile Disposable Vacuum Blood Collection Tube Market

The sterile disposable vacuum blood collection tube market was valued at approximately USD 2.63 billion in 2023 and is expected to reach around USD 5.84 billion by 2034, growing at a steady compound annual growth rate (CAGR) of 7.53% from 2024 to 2034.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5321

Sterile Disposable Vacuum Blood Collection Tube Market Overview
Vacuum blood collection tubes are essential tools in medical testing, designed to safely collect and store blood samples from patients. Made from either glass or plastic, these sterile tubes feature a color-coded rubber stopper that indicates the type of additive inside, such as anticoagulants, clot activators, or preservatives, depending on the intended test. Designed for single use, they ensure sterility and reduce the risk of contamination.

The increasing need for laboratory tests, including biochemical, immunological, diabetes, and tuberculosis screenings, is driving the demand for these tubes. Growing awareness about the importance of sterility to prevent cross-contamination and the rising prevalence of chronic diseases have also fueled market growth. Additionally, investments in healthcare infrastructure and supportive government policies are boosting the adoption of disposable blood collection tubes.

Sterile Disposable Vacuum Blood Collection Tube Market Trends

In October 2023, an Iranian company unveiled a fully automated production line for vacuum blood collection tubes with a remarkable annual capacity of 60 million units. This system operates using advanced ultrasonic nozzle technology.

In May 2023, CML Biotech, one of India’s leading blood collection tube manufacturers, launched the world’s first integrated machine, the “HUSKY-ICHOR,” developed by Husky Technologies. With a setup cost of Rs. 12 crore, this machine can produce 800,000 blood collection tubes daily.

Greiner Bio-One, a global leader in medical diagnostics and biotechnology, reported sales of €637 million in 2023, showcasing its strong presence in the market.

Tech-Driven Innovations in Sterile Disposable Vacuum Blood Collection Tubes

Advanced technologies are transforming the production of sterile disposable vacuum blood collection tubes. Automation now plays a significant role, streamlining processes such as tube loading, detection, and packaging, which ensures consistent quality, sterility, and faster production. This shift allows manufacturers to meet high demand and remain competitive.

The future of blood collection is also being shaped by smart technologies like RFID tags, barcodes, and IoT-enabled tubes. These innovations replace manual labeling, enabling seamless identification and tracking of patient data, reducing errors, and ensuring precise test results in complex laboratory environments.

Top Companies in the Sterile Disposable Vacuum Blood Collection Tube Market

Ajosha Bio Teknik

Becton, Dickinson and Company

Biomall

Bio-x Diagnostics

CML Biotech

GPC Medical, Ltd.

Greiner Bio-One International

Hawach Scientific

KS Medical

Medtronic

Quantum Biomedicals

Sanli Medical

Sarstedt AG & Co. KG

Sekisui Chemical Co. Ltd.

Terumo Corporation

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/sterile-disposable-vacuum-blood-collection-tube-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5321

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 18, 2024
Comprehensive Market Insights Multiple Sclerosis Diagnosis and Treatment (2024 – 2032)
Exploring the Growth of the Multiple Sclerosis Diagnosis and Treatment Market (2024 – 2032)

The global multiple sclerosis diagnosis and treatment market is expected to expand from USD 22.14 billion in 2023 to approximately USD 30.28 billion by 2032. This growth, at a compound annual growth rate (CAGR) of 3.4%, reflects the increasing demand for advanced diagnostic tools and therapeutic options for multiple sclerosis over the next decade.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5140

Report Highlights:
- Technological advancements are playing a key role in the diagnosis and treatment of multiple sclerosis, improving patient outcomes.
- The economic impact of multiple sclerosis is significant, with costs distributed across healthcare systems and patients.
- Early detection of the disease allows for better prevention strategies, ultimately benefiting patients by slowing progression.
- Revenue from multiple sclerosis-related products is being generated by various market players, contributing to the growing industry.
- Relapse-Remitting MS (RRMS), the most common form of the disease, accounted for over 70% of the market share in 2023.
- Medications dominated the market, making up a substantial 81% of total revenue in 2023.
- The Asia Pacific region is expected to experience the highest growth, with a forecasted CAGR of 7.0% throughout the period.
Recent Developments:

In August 2020, Novartis made a groundbreaking advancement in multiple sclerosis treatment with the launch of Kesimpta (ofatumumab). After receiving approval from the U.S. Food and Drug Administration (FDA), Kesimpta became the first self-administered, targeted B-cell therapy for individuals with relapsing multiple sclerosis. This treatment offers significant efficacy and a favorable safety profile, allowing patients to administer the medication at home, addressing a critical need in the management of relapsing forms of MS.

In June 2022, Amneal Pharmaceuticals, Inc. introduced LYVISPAH, an FDA-approved granule formulation designed to manage spasticity in individuals with multiple sclerosis and other spinal cord disorders. Available in dosages of 5, 10, and 20 mg, LYVISPAH provides a much-needed option for improving the quality of life for MS patients in the United States.

Key Companies in the Multiple Sclerosis Diagnosis and Treatment Market:

Siemens Healthineers AG: A leader in medical technology, Siemens Healthineers is known for its cutting-edge diagnostic tools and imaging equipment. The company’s innovations in MRI and other imaging technologies are crucial for the early detection and monitoring of multiple sclerosis.

General Electric Company (GE Healthcare): GE Healthcare provides state-of-the-art diagnostic imaging systems that are essential in the diagnosis of multiple sclerosis. Their MRI systems, in particular, are widely used to detect and monitor the progression of MS.

F. Hoffmann-La Roche Ltd.: Roche is a global leader in biotechnology, offering a range of treatments for multiple sclerosis. Their portfolio includes oral, injectable, and infusion therapies, aimed at reducing the frequency and severity of relapses in MS patients.

Biogen Inc.: Biogen is a pioneer in the field of multiple sclerosis treatment. The company’s portfolio includes some of the most well-known medications, including Tecfidera and Avonex, which are used to manage the symptoms and progression of MS.

Merck & Co., Inc.: Merck offers a variety of medications and therapies for multiple sclerosis. With its strong focus on research and development, Merck continues to drive innovations in the MS treatment landscape, including both oral and infusion treatments.

Novartis AG: Novartis is a leading player in the MS market, known for its groundbreaking therapies such as Gilenya and Kesimpta. The company continues to focus on advancing treatments for MS patients, aiming to improve both efficacy and safety.

Sanofi S.A.: Sanofi is a key player in the multiple sclerosis treatment space, with therapies such as Aubagio and Lemtrada. The company is focused on providing solutions for patients with various forms of MS, from relapsing to progressive types.

Bristol Myers Squibb Company: Bristol Myers Squibb offers innovative treatments for MS, including Zeposia. Their focus is on creating therapies that target the underlying causes of the disease, improving patient outcomes over time.

Teva Pharmaceutical Industries Ltd.: Teva is known for its comprehensive range of MS treatments, including Copaxone and Aubagio. The company’s commitment to making MS treatments more accessible and affordable continues to drive its success in the market.

Abbott Laboratories: Abbott is recognized for its diagnostic solutions in the MS space, including laboratory tests and diagnostic tools that help clinicians assess and monitor the progression of the disease. The company is also involved in developing treatments to alleviate MS symptoms.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/multiple-sclerosis-diagnosis-and-treatment-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5140

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 14, 2024
Healthcare Analytics Market Trends, Growth and Key Players
Healthcare Analytics Market Growth, Trends, and Future Outlook
The healthcare analytics market is projected to expand significantly, with its size expected to rise from USD 42.90 billion in 2023 to approximately USD 241.16 billion by 2032. This growth reflects a compound annual growth rate (CAGR) of 19.1% from 2024 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5141

Report Highlights:

Software components played a major role in the market, holding a 60% share in 2023.

Clinical applications led the market with a 40% share in 2023.

Healthcare providers were the largest market segment in 2023, accounting for 40% of the market.

In 2021, the demand for Electronic Health Record (EHR) systems saw a significant increase, driven by a growing adoption among office-based physicians. Data from the Centers for Disease Control and Prevention revealed that 88.2% of office-based physicians were using an EHR system, with 77.8% of them having a certified system.

Healthcare Analytics: Overview and Importance

Healthcare analytics uses data analysis tools to extract meaningful insights from healthcare data. It involves collecting, processing, and interpreting large volumes of information to improve decision-making, patient care, and operational efficiency in healthcare organizations. By identifying patterns, trends, and connections within the data, healthcare analytics helps healthcare providers, administrators, insurers, and policymakers make informed decisions.

This data can come from a variety of sources, such as Electronic Health Records (EHRs), medical imaging, patient demographics, billing records, and clinical trials. The value of healthcare analytics lies in its ability to drive evidence-based decisions, which lead to better patient outcomes, disease prevention, and personalized treatment plans tailored to individual patient needs.

Recent Developments:

Microsoft introduced Microsoft Cloud for Healthcare in March 2022, a platform designed to improve communication and provide valuable insights between patients and healthcare providers. This innovation aims to enhance patient care by streamlining interactions and providing better tools for healthcare professionals.

Syntellis Performance Solutions expanded its offerings in August 2022 by acquiring Stratasan, a leading provider of healthcare market intelligence and data analytics solutions. This acquisition allows Syntellis to enhance its portfolio, offering healthcare organizations better data-driven tools to support financial, strategic, and operational growth.

Oracle made a significant move in June 2022 by acquiring Cerner Corporation, a well-known player in the clinical healthcare space. This acquisition combines Cerner’s expertise in clinical solutions with Oracle’s strength in analytics, automation, and enterprise platforms, creating a more comprehensive solution for healthcare organizations.

Key Companies in the Healthcare Analytics Market:

Optum Inc.: A healthcare solutions company that provides analytics, software, and services to help improve healthcare efficiency and patient outcomes. Optum integrates healthcare data, technology, and expertise to help organizations make data-driven decisions.

McKesson Corporation: A leader in healthcare supply chain management and pharmacy solutions. McKesson provides data analytics tools to improve healthcare processes, patient care, and operational efficiency across the healthcare sector.

Elsevier: A global information analytics company that specializes in science and health data. Elsevier offers a wide range of healthcare analytics solutions designed to support evidence-based decision-making and improve patient outcomes.

MedeAnalytics Inc.: A provider of cloud-based healthcare analytics solutions that empower healthcare organizations with data-driven insights. MedeAnalytics focuses on helping organizations improve financial, operational, and clinical performance.

Francisco Partners (IBM): Through its acquisition of IBM’s healthcare analytics division, Francisco Partners has become a key player in the healthcare analytics space, offering robust data analysis solutions to healthcare providers and organizations.

Allscripts Healthcare Solutions Inc.: A leading provider of electronic health records (EHR) and other healthcare technology solutions. Allscripts uses data analytics to improve clinical workflows, patient engagement, and healthcare outcomes.

Cerner Corporation: A major provider of healthcare technology and solutions, specializing in electronic health records, population health management, and data analytics to improve healthcare delivery.

IQVIA: A global leader in healthcare analytics, IQVIA offers advanced data and insights solutions for life sciences, healthcare providers, and payers. Their analytics tools support clinical development, commercial operations, and real-world evidence generation.

Oracle: A tech giant that, through its acquisition of Cerner, is strengthening its presence in healthcare analytics. Oracle provides cloud-based healthcare solutions that leverage data analytics to improve operational efficiency and patient care.

SAS Institute, Inc.: A software company specializing in analytics, SAS offers powerful data analytics solutions to the healthcare industry, helping organizations improve decision-making and achieve better patient outcomes.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/healthcare-analytics-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5141

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 14, 2024
Rheumatoid Arthritis Drug Market Insights and Future Outlook (2024 – 2032)
Rheumatoid Arthritis Medications Market Trends and Forecast (2024 – 2032)
In 2023, the global rheumatoid arthritis medications market was valued at approximately USD 17.87 billion. With a steady upward trajectory, it is anticipated to grow to USD 27.38 billion by 2033. This growth reflects a compound annual growth rate (CAGR) of 4.6% throughout the forecast period.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5122

Recent Developments in the Rheumatoid Arthritis Medications Market

In July 2023, Biocon Biologics Ltd, a subsidiary of Biocon Ltd, announced the launch of HULIO (adalimumab fijp) injection in the US. This medication is a biosimilar to Humira (adalimumab) and is designed to treat rheumatoid arthritis, offering a more affordable alternative to the well-established drug.

In February 2022, Pfizer Inc. revealed that the US Food and Drug Administration (FDA) had agreed to review their application for ABRILADA (adalimumab-afib), a biosimilar to Humira. If approved, ABRILADA would offer patients a treatment option that could be interchanged with the original Humira, helping to broaden access to affordable arthritis care.

Also in February 2022, Biogen Inc. partnered with Xbrane Biopharma AB to jointly develop and manufacture Xcimzane, a drug currently in clinical trials. Xcimzane is being developed to be similar to CIMZIA (certolizumab pegol), another widely used medication for treating rheumatoid arthritis, with the aim of providing patients with another effective treatment option in the future.

Key Players in the Rheumatoid Arthritis Drug Market

Boehringer Ingelheim GmbH: A global leader in pharmaceuticals and biologics, Boehringer Ingelheim focuses on innovative treatments for autoimmune diseases like rheumatoid arthritis, with a strong portfolio of biosimilars.

AbbVie: Known for Humira, AbbVie has been a dominant player in the rheumatoid arthritis treatment space. The company continues to innovate with new therapies and biosimilars to address unmet patient needs.

Novartis: With a wide range of treatments for autoimmune diseases, Novartis is a significant player in the rheumatoid arthritis market, working on both biologic drugs and small molecule therapies.

Pfizer Inc.: Pfizer is a key contributor to the market with its offerings like Xeljanz (tofacitinib) and the biosimilar ABRILADA, continuing to expand its portfolio of rheumatoid arthritis medications.

Bristol Myers Squibb: The company is known for its biologic therapies such as Orencia (abatacept) and its continued efforts to develop next-generation treatments for rheumatoid arthritis.

F. Hoffmann-La Roche Ltd.: Roche offers multiple rheumatoid arthritis treatments, including Actemra (tocilizumab), and is committed to ongoing research into innovative therapies for autoimmune conditions.

Johnson & Johnson: A major player with treatments like Remicade (infliximab), J&J is at the forefront of developing therapies that improve the quality of life for rheumatoid arthritis patients.

Regeneron Pharmaceuticals, Inc.: Regeneron is involved in developing cutting-edge immunotherapies, including Dupixent (dupilumab), for conditions like rheumatoid arthritis and other autoimmune diseases.

Amgen, Inc.: Known for its biologics, Amgen offers Enbrel (etanercept), a widely used treatment for rheumatoid arthritis, and continues to research and develop new therapies for autoimmune conditions.

Merck KGaA: With a focus on immunology, Merck is advancing its presence in the rheumatoid arthritis market, exploring new therapies that offer improved outcomes for patients.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/rheumatoid-arthritis-drugs-market-sizing

Access exclusive insight now @ https://www.towardshealthcare.com/price/5122

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 14, 2024
Ambulatory Surgical Center Market Key Companies, Developments and Future Trends
Future Outlook and Key Players in the Ambulatory Surgical Center Market

The ambulatory surgical center (ASC) market was valued at USD 94.57 billion in 2022 and is expected to reach USD 167.1 billion by 2032. With a projected compound annual growth rate (CAGR) of 5.66% from 2023 to 2032, the market is set for significant expansion in the coming years.

Ambulatory surgery centers (ASCs) are specialized medical facilities that provide outpatient surgical services, meaning patients can have surgery and go home on the same day without needing to stay overnight. Before ASCs emerged in the 1970s, most surgeries were performed in hospitals. While hospitals are known for delivering high-quality care, patients opting for elective surgeries often face long wait times and limited availability of operating rooms. In contrast, ASCs have become a popular choice for many patients in recent years because they offer more flexible scheduling, a calmer and more comfortable setting, and lower costs.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5021

Ambulatory Surgical Center Market Companies
1. Cerner Corporation – A leading global health information technology company, Cerner focuses on providing innovative electronic health record (EHR) solutions, empowering healthcare organizations to improve patient care and streamline operations.
2. Allscripts Healthcare Solutions Inc. – Allscripts offers healthcare IT solutions, including EHRs and practice management tools, designed to improve patient outcomes and enhance operational efficiency in various healthcare settings.
3. McKesson Corporation – McKesson is a major player in healthcare distribution and technology solutions, providing medical supplies, pharmaceuticals, and services to improve healthcare systems worldwide.
4. Medical Information Technology Inc. (MEDITECH) – MEDITECH is known for its EHR systems that help healthcare providers manage patient information, streamline workflows, and improve care coordination.
5. Advanced Data Systems Corporation – Specializing in healthcare software solutions, Advanced Data Systems offers integrated electronic health records, practice management software, and scheduling solutions for healthcare providers.
6. Surgical Information Systems (SIS) – SIS provides specialized software solutions for surgery centers, offering tools that improve clinical workflows, enhance patient care, and optimize business operations.
7. NextGen Healthcare – A provider of EHR and practice management solutions, NextGen Healthcare supports outpatient facilities with comprehensive software designed to improve care delivery and operational efficiency.
8. Philips Healthcare – A global leader in health technology, Philips Healthcare offers advanced medical imaging, monitoring, and therapeutic solutions that support the entire healthcare system, including ambulatory surgical centers.
9. Epic Systems Corporation – Epic Systems develops EHR software that helps healthcare organizations manage patient records and optimize care workflows, making it widely used in both hospitals and outpatient settings.
10. GE Healthcare – GE Healthcare provides a broad range of healthcare technology, including medical imaging, monitoring, and diagnostic solutions, aimed at improving the efficiency and quality of patient care.
Key Developments
- GE Healthcare launched Edison Datalogue, a solution designed to manage and analyze healthcare data. This innovation helps improve patient care and streamline operations by enhancing data management capabilities.
- In 2019, MEDITECH and Google partnered to make electronic health record (EHR) data accessible on the Google Cloud Platform. This collaboration boosted the security, scalability, and interoperability of patient data, ensuring better patient care across healthcare systems.
- Epic Systems and Teladoc Health joined forces in 2019 to integrate Teladoc’s virtual care platform with Epic’s App Orchard. This partnership enabled healthcare providers to offer telehealth video consultations, making healthcare more accessible and convenient for patients.
- Terveystalo acquired Attendo’s Finnish healthcare services in December 2018, with the merger set to start in January 2019. This acquisition strengthened Terveystalo’s position in the Finnish healthcare market, expanding its reach and service offerings.
- In May 2018, AMSURG acquired Horizon Eye & LASIK Center, adding ophthalmology services to its network of ambulatory surgery centers. This expansion allowed AMSURG to offer a wider range of surgical services, improving patient care.
- AmSurg Corporation merged with Envision Healthcare Holdings Inc. in June 2016. This merger created a healthcare powerhouse with a broad range of services and innovative solutions, enhancing patient care and offering greater opportunities for healthcare professionals.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/factors-influencing-the-ambulatory-surgical-center-industry

Access exclusive insight now @ https://www.towardshealthcare.com/price/5021

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 14, 2024
Transforming Oral Healthcare A Comprehensive Analysis of the Dental Services Market

Exploring the Growth of the Dental Services Market Trends and Future Outlook

The global dental services market was valued at USD 432.1 billion in 2022 and is projected to reach USD 699.7 billion by 2032, growing at a steady annual rate of 4.93% between 2023 and 2032. This growth is largely driven by rising awareness and demand for cosmetic dentistry, along with an increasing focus on oral health worldwide.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5022

Impact of COVID-19 on Dental Care

The COVID-19 pandemic significantly disrupted dental care. In the early months of the outbreak, many dental offices closed except for emergencies. Even after reopening, patient volume remained low. A survey by the American Dental Association in August 2020 found that while nearly all dentists had reopened, over half reported fewer patients than usual. Initially, the ADA advised postponing non-urgent procedures, including routine checkups, cleanings, and cosmetic surgeries, while emergency services continued for issues like painful cavities and facial injuries.

Does Covid Affect Dental Care?

The COVID-19 epidemic has had a tremendous impact on the healthcare system, particularly the dental industry. When the virus first expanded across the United States in March and April, many dentist offices closed save for emergencies. Even after they reopened, changes were still evident. A study of dentists by the American Dental Association during the week of August 10 found that 98.9% of them were open, but that only 47.6% reported “business as usual” and 51.3% reported “lower patient volume than usual.”

According to data from the American Dental Association’s Health Policy Institute (HPI), the dental industry was at a standstill as a result of COVID-19 since dental clinics were only allowed for emergency cases in the early phases of the pandemic. In March 2020, the American Dental Association (ADA) issued a public advisory urging people to postpone elective dental procedures. The ADA lists the procedures that are required to be postponed as oral exams, radiography, routine cleanings, cosmetic surgeries, and orthodontic procedures without pain medication. Dental or facial traumas, painful caries, oral bleeding, and abnormal tissue biopsies, emergency dental services were offered.

Segmentation Outlook

The largest share of the dental services market has been in the endodontic procedures sector. Over the past two decades, advancements in technology, materials, and treatment methods have transformed this area of dental care. Innovations such as bioceramics, rotating Ni-Ti files, digital radiography, improved irrigation techniques, and CBCT 3D imaging have enhanced the way endodontic treatments are performed. These developments have also raised the distinction between the care provided by specialists versus general dentists, especially when dealing with teeth that have complex structures. As dental health issues in the U.S. continue to rise, this sector is expected to grow further.

The preventive dental services segment also holds a significant share of the dental services market. As consumers have become more aware of the importance of oral health, the demand for preventive services like teeth cleaning and fluoride treatments has surged. However, the COVID-19 pandemic caused many dental offices to close or reduce operating hours, limiting access to routine and preventive care. Despite these setbacks, the pandemic also created an opportunity for the dental industry to shift focus toward non-invasive, prevention-based care methods that do not involve aerosol-generating procedures. If restrictions are eased, this shift could improve access to oral healthcare in the future.

Access exclusive insight now @ https://www.towardshealthcare.com/price/5022

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

November 14, 2024
Leading Companies in the Cell and Gene Therapy Manufacturing Market
Growth Trends in the Cell and Gene Therapy Manufacturing Market

The global cell and gene therapy manufacturing market was valued at approximately USD 3.76 billion in 2022 and is projected to grow to around USD 13.60 billion by 2032, reflecting a compound annual growth rate (CAGR) of 16.25% from 2023 to 2032.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5024

Cell and gene therapy has generated significant interest due to its potential to treat cancer. As this complex and rapidly growing industry expands, Contract Development and Manufacturing Organizations (CDMOs) are playing a key role in helping businesses streamline the manufacturing process for these therapies.

In August 2022, Cytiva, a subsidiary of Danaher Corporation, partnered with Forecyte Bio, a CDMO specializing in cell and gene therapy, to accelerate the development and production of these therapies in both China and the U.S. Through this collaboration, Forecyte Bio will leverage Cytiva’s Flex Factory platform to launch and expand its CDMO services.

Leading Companies in the Cell and Gene Therapy Manufacturing Market
1. Bluebird Bio Inc.
  A pioneer in gene therapy, Bluebird Bio focuses on developing innovative therapies for genetic diseases and cancer. The company’s expertise lies in the manufacturing of cell and gene therapies, helping to advance treatments with high unmet needs.
2. Hitachi Chemical Co., Ltd.
  Now known as Showa Denko Materials, Hitachi Chemical is involved in the development and production of advanced biopharmaceutical products, including cell and gene therapies, offering solutions for various stages of therapy manufacturing.
3. Takara Bio Inc.
  Takara Bio specializes in biotechnology, providing a wide range of services from gene therapy development to production. Their advanced manufacturing platforms support the commercialization of cell-based therapies.
4. Catalent Inc.
  Catalent is a leading provider of advanced delivery technologies, development services, and manufacturing solutions for biologics. The company plays a critical role in cell and gene therapy production through its robust platform offerings.
5. F. Hoffmann-La Roche Ltd.
  Roche is a global leader in healthcare, with a strong focus on personalized treatments, including cell and gene therapies. The company is deeply invested in advancing these therapies to address serious medical conditions such as cancer and genetic disorders.
6. Samsung Biologics
  A major player in the biopharmaceutical manufacturing industry, Samsung Biologics provides comprehensive contract manufacturing services for cell and gene therapies. Its state-of-the-art facilities and expertise support the growth of advanced biologic therapies.
7. Novartis AG
  Novartis is at the forefront of gene therapy innovation, with its well-known therapies like Kymriah. The company focuses on bringing advanced gene and cell therapies from development to commercial production, aiming to transform patient care.
8. Lonza
  Lonza is a global leader in the biopharmaceutical manufacturing sector, offering contract services for cell and gene therapy development. The company’s capabilities are key to the production of complex, personalized medicine.
9. Merck KGaA
  Merck KGaA, Darmstadt, Germany, is a science and technology company heavily invested in cell and gene therapy. The company provides technologies and services that aid in the development, manufacturing, and commercialization of these innovative therapies.
10. Wuxi Advanced Therapies
  Wuxi Advanced Therapies is known for its contract development and manufacturing services for cell and gene therapies. The company offers end-to-end solutions from research and development to commercial-scale production.
11. Boehringer Ingelheim
  Boehringer Ingelheim provides contract manufacturing services and solutions for gene therapy, offering a wide range of capabilities to bring cell and gene-based treatments to the market.
12. Cellular Therapeutics
  Cellular Therapeutics specializes in the production of cell-based therapies, with a focus on offering innovative solutions to support clinical and commercial-scale manufacturing of cell and gene therapies.
13. Miltenyi Biotec
  Miltenyi Biotec provides cutting-edge technologies for cell and gene therapy manufacturing, from cell processing to final therapy production. The company’s products and services are designed to advance the field of cellular medicine.
14. Thermo Fisher Scientific
  Thermo Fisher Scientific plays a pivotal role in the development and manufacturing of gene and cell therapies. The company offers comprehensive solutions to support every phase of the production process, from discovery to commercial-scale manufacturing.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/cell-and-gene-therapy-manufacturing-market-experiencing-significant-growth

Access exclusive insight now @ https://www.towardshealthcare.com/price/5024

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
November 14, 2024
CAR T-Cell Therapy Market Key Players, Partnerships and Growth Opportunities

CAR T-Cell Therapy Market Growth, Trends, and Key Players (2023-2032)

The global CAR T-cell therapy market is projected to expand significantly, growing from USD 3.87 billion in 2022 to an estimated USD 88.52 billion by 2032, reflecting a robust compound annual growth rate (CAGR) of 29.8% from 2023 to 2032. This growth is driven by ongoing clinical trials and the increasing incidence of cancer, highlighting the rising demand for advanced cancer treatments.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5028

The United States and China have led the way in CAR T-cell therapy trials, with Europe trailing behind in the number of clinical studies listed on ClinicalTrials.gov.

CAR T-cell therapies hold immense promise in revolutionizing cancer treatment by harnessing the body’s immune system to fight cancer. These therapies involve genetically modifying a patient’s T cells to express a chimeric antigen receptor (CAR) that specifically targets cancer cells, offering a personalized treatment approach.

Often referred to as a “miracle anticancer drug” due to their high success rates, CAR T-cell therapies involve a complex manufacturing process. This process includes collecting the patient’s T cells at a medical facility, then culturing them in specialized labs to create a treatment tailored to the individual. The key advantages of CAR T-cell therapy over traditional treatments are its ability to use the body’s own immune system to attack cancer cells, faster recovery times, and shorter treatment durations. Additionally, CAR T-cell therapies have the unique ability to remain active in the body, recognizing and targeting cancer cells even if the cancer returns.

Currently, CAR T-cell therapy is mainly used to treat cancers such as lymphoma, acute lymphocytic leukemia, and multiple myeloma. With its many benefits over conventional medications, CAR T-cell therapy has seen widespread adoption, driving significant growth in the market.

CAR T-Cell Therapy Market Companies

1. Johnson & Johnson Services, Inc.

Johnson & Johnson, a global leader in healthcare, has a strong presence in the CAR T-cell therapy market. The company’s expertise in immunotherapy is demonstrated by its innovative pipeline, including the development of CAR T-cell therapies for various cancers. Johnson & Johnson has worked on several partnerships to advance the potential of cell therapies, including collaboration with other pharmaceutical giants to bring breakthrough treatments to market.

2. Allogene Therapeutics

Allogene Therapeutics focuses on developing allogeneic (off-the-shelf) CAR T-cell therapies, which are designed to be more readily available and less costly than autologous CAR T therapies, where a patient’s own cells are used. Allogene’s pioneering work in the field aims to overcome some of the challenges related to the manufacturing complexities and costs associated with traditional CAR T therapies.

3. Lonza

Lonza is a global leader in the development and manufacturing of biologics, including CAR T-cell therapies. The company provides cell therapy manufacturing services to several pharmaceutical companies, assisting in the large-scale production of CAR T-cell therapies. Lonza’s expertise in gene and cell therapy manufacturing has made it an integral player in the CAR T market, ensuring the quality and scalability of these therapies.

4. Aurora Biopharma

Aurora Biopharma specializes in developing next-generation CAR T-cell therapies. Its focus is on improving the efficacy and safety of cell-based therapies for cancer treatment. Aurora Biopharma is dedicated to advancing its proprietary therapies for hematologic and solid tumor cancers, and it is working on enhancing the manufacturing process to make these therapies more accessible to patients.

5. Cartesian Therapeutics, Inc.

Cartesian Therapeutics is an innovative biotech company focused on the development of engineered T-cell therapies, including CAR T-cells, for the treatment of cancer and autoimmune diseases. The company is committed to advancing its proprietary platform to create highly effective and durable treatments, with a focus on leveraging mRNA technology to enhance the CAR T-cell production process.

6. Novartis

Novartis is one of the pioneers in the CAR T-cell therapy market, having launched Kymriah, the first FDA-approved CAR T-cell therapy for certain types of leukemia and lymphoma. Novartis continues to lead in CAR T-cell research and development, focusing on expanding the range of cancers that CAR T therapy can treat. Their ongoing trials and collaborations aim to improve the accessibility and outcomes of CAR T therapy.

7. Bristol-Myers Squibb

Bristol-Myers Squibb (BMS) has made significant contributions to the CAR T-cell therapy field, particularly through its acquisition of Celgene, which brought the CAR T-cell therapy Breyanzi (lisocabtagene maraleucel) to its portfolio. BMS continues to invest heavily in CAR T research, with several trials exploring new indications and improving treatment efficacy.

8. Gilead Sciences

Gilead Sciences is a leader in cell therapy through its acquisition of Kite Pharma, which developed Yescarta, one of the most widely used CAR T-cell therapies for treating certain lymphomas. Gilead is focused on expanding the indications for CAR T therapies, including exploring treatments for solid tumors. The company is also working to refine the manufacturing process to improve the cost-effectiveness and accessibility of CAR T therapies.

9. Curocell Inc.

Curocell Inc. is an emerging player in the CAR T-cell therapy market, focusing on the development of its proprietary therapies for cancer treatment. The company is advancing new CAR T-cell products that target a variety of cancers, including both hematologic malignancies and solid tumors. Curocell is dedicated to refining its CAR T therapies and improving patient outcomes through innovative treatments.

10. JW Therapeutics

JW Therapeutics is a leading Chinese biotechnology company that specializes in developing CAR T-cell therapies for cancer. The company is focused on improving the safety and efficacy of CAR T therapies while expanding their accessibility. JW Therapeutics is advancing its pipeline of CAR T therapies for the treatment of blood cancers, with a focus on lymphoma and leukemia.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/car-t-cell-therapies-are-poised-for-the-next-wave-of-innovation

Access exclusive insight now @ https://www.towardshealthcare.com/price/5028

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

November 14, 2024
Acne Treatment Market Key Developments and Leading Companies

Global Acne Treatment Market Growth, Key Players, and Future Outlook

The global acne treatment market is projected to expand from USD 9,615.6 million in 2022 to approximately USD 15,183.2 million by 2032, growing at a compound annual growth rate (CAGR) of 4.8% from 2023 to 2032. This growth is primarily driven by increasing clinical approvals and the launch of innovative products aimed at effectively treating acne.

Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5037

Dermatology Clinics Fueling Acne Treatment Market Growth

Dermatology clinics are playing a key role in driving the expansion of the acne treatment market. These specialized clinics offer comprehensive care for various skin issues, including acne. They provide a variety of treatment options, ranging from medications and therapies to cosmetic procedures, all tailored to address acne concerns.

In addition, dermatology clinics are investing in cutting-edge technologies and treatments to enhance the effectiveness of acne care. Many now utilize advanced tools like laser therapy and photodynamic therapy, which have been proven to reduce acne lesions and improve the overall appearance of the skin.

Recent Developments in the Acne Treatment Market Company Announcements

In May 2023, Bausch Health Companies Inc. and its dermatology subsidiary, Ortho Dermatologics, revealed that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for IDP-126, a treatment currently under investigation. This marks a significant step forward for the company in advancing acne treatment options.

In July 2022, Glenmark Pharmaceuticals introduced MINYM, a topical Minocycline 4% Gel for the treatment of moderate to severe acne. Minocycline is a potent antibacterial gel with notable anti-inflammatory effects, and it is distinguished by having the lowest MIC90 compared to other topical antibacterial formulations.

In March 2022, Galderma launched Twyneo cream in the U.S., a topical treatment for acne vulgaris in patients aged 9 years or older. Twyneo is a fixed-dose combination of benzoyl peroxide (3%) and tretinoin (0.1%), offering a dual-action solution for acne care.

In November 2021, Sun Pharmaceutical Industries introduced Winlevi cream in the U.S. market for the treatment of acne vulgaris. Winlevi had previously received FDA approval in August 2020 and has since become a recognized acne treatment.

In June 2020, Thayer expanded its product offerings with a new acne-tailored skincare line, catering to the specific needs of individuals battling acne, providing targeted solutions for skincare and acne management.

Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/acne-treatment-market

Access exclusive insight now @ https://www.towardshealthcare.com/price/5037

We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

Visit Dental Specifics: https://www.towardsdental.com

Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

November 14, 2024